HIV感染者使用一线整合酶抑制剂治疗后的糖尿病发生率:法国多中心回顾性研究
多因素及生存分析未发现INSTI与NNRTI或PI相比新发糖尿病风险增加,但BMI>30 kg/m2、年龄>37岁(生存分析中)、黑人或西班牙裔、高血压及艾滋病与糖尿病发生比例较高相关。
要点
- INSTI作为第三药物与NNRTI或PI相比,新发糖尿病风险无统计学差异。
- BMI>30 kg/m2、高龄、黑人或西班牙裔、高血压及艾滋病与更高糖尿病发生比例相关。
- 临床仍需警惕INSTI可能代谢合并症,尤其高BMI及老年患者。
核心结论
- INSTI作为第三药物的cART与NNRTI或PI相比,新发糖尿病风险无统计学增加。
- 临床应关注高BMI及老年患者等高风险人群的代谢合并症。
研究设计与样本
- 法国Dat'AIDS多中心回顾性队列研究(ClinicalTrials.gov NCT02898987)。
- 比较以INSTI、NNRTI或PI为第三药物的cART后新发糖尿病风险。
主要发现
- 多因素及生存分析未显示INSTI较NNRTI或PI增加新发糖尿病。
- BMI>30 kg/m2、年龄>37岁(生存分析中)、黑人或西班牙裔、高血压及艾滋病与更高新发糖尿病比例相关。
临床怎么用
- 临床处方INSTI时无需因糖尿病风险顾虑而避免使用。
- 对高BMI及老年患者应加强代谢监测。
局限性
- 回顾性研究设计。
- 糖尿病定义依赖病史记录、HbA1c>7.5%或启动降糖治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Integrase strand transfer inhibitors (INSTIs) are increasingly used in patients living with HIV due to their safety, effectiveness and high genetic barrier. However, an association with weight gain has recently been suggested and several cases of diabetes mellitus have been reported with raltegravir and dolutegravir. The long-time metabolic impact of these recent molecules remains unclear. OBJECTIVES: To assess if an INSTI as a third agent is statistically associated with new-onset diabetes mellitus compared with an NNRTI or a PI. PATIENTS AND METHODS: Patients undergoing first-line combined ART (cART) without diabetes at baseline were retrospectively included from the Dat'AIDS French cohort study (ClinicalTrials.gov NCT02898987). Incident diabetes mellitus was defined as a notification of new diabetes in the medical history, a glycated haemoglobin (HbA1c) level superior to 7.5% or the start of a diabetes therapy following the initiation of ART. RESULTS: From 2009 to 2017, 19 462 patients were included, among which 265 cases of diabetes mellitus occurred. Multivariate and survival analyses did not highlight an increase in new-onset diabetes in patients undergoing cART with an INSTI as a third agent compared with an NNRTI or a PI. BMI >30 kg/m2, age >37 years old (in survival analysis), black race or Hispanic ethnicity, arterial hypertension and AIDS were associated with a higher proportion of incident diabetes. CONCLUSIONS: INSTIs were not statistically associated with new-onset diabetes. However, clinicians should remain aware of this possible metabolic comorbidity, particularly in patients with a high BMI and older patients.
引用
- Ursenbach A, Max V, Maurel M, et al. Incidence of diabetes in HIV-infected patients treated with first-line integrase strand transfer inhibitors: a French multicentre retrospective study. J Antimicrob Chemother. 2020. PMID: 32791523. doi:10.1093/jac/dkaa330
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。